Clinical course and outcomes of Iranian children with juvenile dermatomyositis and polymyositis

被引:12
|
作者
Malek, Abdolreza [1 ]
Raeeskarami, Seyed-Reza [1 ,2 ]
Ziaee, Vahid [1 ,2 ,3 ,4 ]
Aghighi, Yahya [2 ]
Moradinejad, Mohamad-Hassan [3 ,4 ]
机构
[1] Univ Tehran Med Sci, Rheumatol Res Ctr, Pediat Rheumatol Res Grp, Tehran, Iran
[2] Univ Tehran Med Sci, Dept Pediat, Tehran, Iran
[3] Univ Tehran Med Sci, Growth & Dev Res Ctr, Tehran, Iran
[4] Pediat Ctr Excellence, Childrens Med Ctr, Tehran, Iran
关键词
Children; Clinical course; Dermatomyositis; Outcome; Polymyositis; IDIOPATHIC INFLAMMATORY MYOPATHIES; CHILDHOOD; LIPODYSTROPHY; MULTICENTER; CALCINOSIS; ARTHRITIS; FEATURES; REGISTRY; DISEASE; ONSET;
D O I
10.1007/s10067-014-2675-2
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
This study evaluated the clinical features, course, and outcomes of Iranian children with juvenile dermatomyositis (JDM), juvenile polymyositis (JPM), and other uncommon connective tissue disorders. A chart review of 85 Iranian children with JDM and JPM was performed during a 10-year period from 2003 to 2013. The patients' clinical signs and symptoms, laboratory data, and other factors affecting clinical outcomes were recorded using questionnaires. Statistical analysis was performed using SPSS software version 20. In all, 40 boys and 45 girls were included in the study (F/M, 1.1:1). Disease frequency was significantly higher in boys aged < 5 years (F/M, 0.4:1) and girls aged > 5 years (F/M, 1.6:1). The combined mean age at diagnosis was 7.5 years. Muscle weakness, particularly in the proximal muscles of lower extremities (96 %); fatigue (83 %); and heliotrope rash (71 %) were the most frequently recorded symptoms. Elevated lactate dehydrogenase level was the most common enzyme disturbance (98 %). Monocyclic course was seen in 60 % of patients. The mean treatment duration was 3 years. The incidence rate of complications such as calcinosis, lipodystrophy, and growth disturbances was 20, 9, and 30 %, respectively. The occurrence of these complications in patients with monocyclic disease was significantly lower. Vital organ involvement led to the death of four patients. The incidence of calcinosis was significantly lower in patients having a shorter interval between disease onset and treatment. Two important complications, failure to thrive and lipodystrophy, were significantly higher in patients having antinuclear antibodies. The incidence of the above three complications was higher in patients with polycyclic or continuous chronic disease. Respiratory failure was the most common cause of patient mortality.
引用
收藏
页码:1113 / 1118
页数:6
相关论文
共 50 条
  • [1] Clinical course and outcomes of Iranian children with juvenile dermatomyositis and polymyositis
    Abdolreza Malek
    Seyed-Reza Raeeskarami
    Vahid Ziaee
    Yahya Aghighi
    Mohamad-Hassan Moradinejad
    Clinical Rheumatology, 2014, 33 : 1113 - 1118
  • [2] Characterization of the biomarkers related to the clinical course and outcomes of juvenile dermatomyositis
    Lin, Ting -Wei
    Hu, Ya-Chiao
    Chiang, Bor-Luen
    JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION, 2023, 56 (02) : 416 - 423
  • [3] Clinical features and outcome in a Danish cohort of juvenile dermatomyositis patients
    Mathiesen, P. R.
    Zak, M.
    Herlin, T.
    Nielsen, S. M.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2010, 28 (05) : 782 - 789
  • [4] Pregnancy outcomes in dermatomyositis and polymyositis patients
    Missumi, Larissa Sayuri
    Carlos de Souza, Fernando Henrique
    Andrade, Joelma Queiroz
    Shinjo, Samuel Katsuyuki
    REVISTA BRASILEIRA DE REUMATOLOGIA, 2015, 55 (02) : 95 - 102
  • [5] Clinical analysis and outcome of interstitial lung disease complicated with juvenile dermatomyositis and juvenile polymyositis
    Sato, Satoshi
    Uejima, Yoji
    Nanbu, Meika
    Suganuma, Eisuke
    Takano, Tadamasa
    Tanaka, Risa
    Kabuki, Tomoyuki
    Oguma, Eiji
    Oh-Ishi, Tsutomu
    Kawano, Yutaka
    MODERN RHEUMATOLOGY, 2017, 27 (04) : 652 - 656
  • [6] Clinical features and disease course of patients with juvenile dermatomyositis
    Gowdie, Peter J.
    Allen, Roger C.
    Kornberg, Andrew J.
    Akikusa, Jonathan D.
    INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2013, 16 (05) : 561 - 567
  • [7] Clinical Characteristics and Outcomes of Juvenile and Adult Dermatomyositis
    Na, Sang-Jun
    Kim, Seung Min
    Sunwoo, Il Nam
    Choi, Young-Chul
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2009, 24 (04) : 715 - 721
  • [8] Comparison of clinical features and drug therapies among European and Latin American patients with juvenile dermatomyositis
    Guseinova, D.
    Consolaro, A.
    Trail, L.
    Ferrari, C.
    Pistorio, A.
    Ruperto, N.
    Buoncompagni, A.
    Pilkington, C.
    Maillard, S.
    Oliveira, S. K.
    Sztajnbok, F.
    Cuttica, R.
    Corona, F.
    Katsicas, M. M.
    Russo, R.
    Ferriani, V.
    Burgos-Vargas, R.
    Solis-Vallejo, E.
    Bandeira, M.
    Baca, V.
    Saad-Magalhaes, C.
    Silva, C. A.
    Barcellona, R.
    Breda, L.
    Cimaz, R.
    Gallizzi, R.
    Garozzo, R.
    Martino, S.
    Meini, A.
    Stabile, A.
    Martini, A.
    Ravelli, A.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2011, 29 (01) : 117 - 124
  • [9] Pregnancy course and outcomes of patients with polymyositis and dermatomyositis (PM/DM) managed in a single center
    Mino, Rina
    Shimada, Hiromi
    Wakiya, Risa
    Nakashima, Shusaku
    Miyagi, Taichi
    Sugihara, Koichi
    Ushio, Yusuke
    Mizusaki, Mao
    Chujo, Kanako
    Kameda, Tomohiro
    Kanenishi, Kenji
    Kadowaki, Norimitsu
    Dobashi, Hiroaki
    MEDICINE, 2023, 102 (14) : E33462
  • [10] Favorable outcomes with reduced steroid use in juvenile dermatomyositis
    Orandi, Amir B.
    Fotis, Lampros
    Lai, Jamie
    Morris, Hallie
    White, Andrew J.
    French, Anthony R.
    Baszis, Kevin W.
    PEDIATRIC RHEUMATOLOGY, 2021, 19 (01)